quotes and stock data may be delayed 15 minutes
52 wk low
52 wk hi
Burn Rate (Qtr)
Click on drug name or indication to see upcoming trial info, prior data, and more general information.
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
MYFEMBREE (Relugolix) (GnRH receptor antagonist)
Uterine fibroids, Uterine disease, Benign tumor
Relugolix combo tablet (gonadotropin-releasing hormone receptor agonist)
Infertility, Contraceptive, Uterine fibroids
search in progress
Pipeline powered by
We aspire to be the leading healthcare company focused on redefining care for women’s health and prostate cancer. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer. We strive to improve the lives of millions of people, while building an innovative, dynamic, and collaborative company where employees thrive.
See what the community is saying - click to see full post.